GlassScriptPhysician profile
Christopher Patrick Albergo
NPI 1396156147
$9,137.98
in general payments reported to CMS, 2019-2025
67 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $1,011 · 2021: $1,876 · 2022: $2,222 · 2023: $1,348 · 2024: $1,207 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.14 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $827.11 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $735.28 | 2021-2024 | Korlym |
| Amgen INC. | $649.06 | 2020-2025 | Tepezza, Evenity, Repatha |
| Lilly USA, LLC | $477.38 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Ascensia Diabetes Care US INC. | $360.39 | 2022-2023 | |
| Abbvie INC. | $359.12 | 2020-2025 | Synthroid |
| Astrazeneca Pharmaceuticals LP | $356.18 | 2020-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $336.15 | 2020-2024 | |
| Medtronic, INC. | $325.52 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $279.93 | 2021-2024 | Omnipod |
| Zealand Pharma US, INC. | $226.24 | 2020-2022 | |
| Cequr Corporation | $216.95 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $214.66 | 2020-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $209.08 | 2020-2025 | Tirosint, Licart, Licart |
| Dexcom, INC. | $180.46 | 2021-2025 | Dexcom G6 Transmitter |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Albergo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.